← Back to Screener
Enveric Biosciences, Inc. Common Stock (ENVB)
Price$2.35
Favorite Metrics
Price vs S&P 500 (26W)-79.38%
Price vs S&P 500 (4W)-4.83%
Market Capitalization$3.83M
All Metrics
Book Value / Share (Quarterly)$15.83
P/TBV (Annual)2.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.35%
Cash Flow / Share (Quarterly)$-35.13
Price vs S&P 500 (YTD)-46.72%
Gross Margin (TTM)20.42%
Net Profit Margin (TTM)-14.05%
EPS (TTM)$-89.80
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-89.80
EPS (Annual)$-228.47
ROI (Annual)-601.14%
Gross Margin (Annual)20.42%
Net Profit Margin (5Y Avg)-18.30%
Cash / Share (Quarterly)$17.21
Revenue Growth QoQ (YoY)-11.87%
ROA (Last FY)-310.62%
Revenue Growth TTM (YoY)-7.16%
EBITD / Share (TTM)$-51.68
ROE (5Y Avg)-406.21%
Operating Margin (TTM)-15.88%
Cash Flow / Share (Annual)$-136.75
P/B Ratio1.11x
P/B Ratio (Quarterly)0.60x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)0.00x
Net Interest Coverage (TTM)-5642.00x
ROA (TTM)-241.87%
EPS Incl Extra (Annual)$-228.47
Current Ratio (Annual)1.84x
Quick Ratio (Quarterly)4.19x
3-Month Avg Trading Volume0.71M
52-Week Price Return-86.68%
Revenue / Employee (TTM)$8
Tangible BV / Share (Quarterly)$8.66
P/S Ratio (Annual)0.10x
Asset Turnover (Annual)1.58x
52-Week High$17.84
Operating Margin (5Y Avg)-16.30%
EPS Excl Extra (Annual)$-228.47
Tangible BV CAGR (5Y)-26.11%
26-Week Price Return-75.39%
Quick Ratio (Annual)1.50x
13-Week Price Return-46.86%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.60x
Enterprise Value$0.074
Asset Turnover (TTM)1.43x
Book Value / Share Growth (5Y)-51.61%
Revenue / Employee (Annual)$8
Inventory Turnover (Annual)2.60x
Pretax Margin (Annual)-13.08%
Cash / Share (Annual)$39.66
3-Month Return Std Dev88.40%
Gross Margin (5Y Avg)23.50%
Net Income / Employee (TTM)$-2
ROE (Last FY)-601.14%
Net Interest Coverage (Annual)-5414.54x
EPS Basic Excl Extra (Annual)$-228.47
P/FCF (TTM)22.54x
Receivables Turnover (TTM)5.60x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-89.80
Receivables Turnover (Annual)5.60x
ROI (TTM)-349.10%
P/S Ratio (TTM)0.10x
Pretax Margin (5Y Avg)-18.38%
Revenue / Share (Annual)$3991.00
Tangible BV / Share (Annual)$27.44
Price vs S&P 500 (52W)-116.51%
Year-to-Date Return-44.08%
5-Day Price Return-0.49%
EPS Normalized (Annual)$-228.47
ROA (5Y Avg)-231.58%
Net Profit Margin (Annual)-14.03%
Month-to-Date Return4.64%
Cash Flow / Share (TTM)$-10.58
EBITD / Share (Annual)$-220.72
Operating Margin (Annual)-15.84%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-406.21%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-89.80
P/TBV (Quarterly)1.37x
P/B Ratio (Annual)2.29x
Inventory Turnover (TTM)19.00x
Pretax Margin (TTM)-13.05%
Book Value / Share (Annual)$28.19
Price vs S&P 500 (13W)-47.55%
Beta0.47x
P/FCF (Annual)11.61x
Revenue / Share (TTM)$3992.00
ROE (TTM)-349.10%
52-Week Low$1.75
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ENVBEnveric Biosciences, Inc. Common Stock | 0.10x | -7.16% | 20.42% | — | $2.35 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Enveric Biosciences develops novel small-molecule therapeutics targeting depression, anxiety, addiction, and other psychiatric disorders through neuroplastogenicity. Its lead program, EB-003, is a first-in-class candidate designed to promote neuroplasticity without inducing hallucinations. The company is also advancing EB-002, a synthetic psilocin prodrug, as a next-generation treatment for psychiatric disorders.